Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 20, 2001New England Journal of MedicineOpen Access

Spironolactone in Addition to ACE Inhibition to Reduce Proteinuria in Patients with Chronic Renal Disease

View Full Paper
Ask AI
Bookmark
Share

Key result

Spironolactone added to ACE inhibition reduces proteinuria in patients with chronic renal disease.

Why the study?

Does spironolactone in addition to ACE inhibition reduce proteinuria in patients with chronic renal disease?

Population

Patients with chronic renal disease

Design

Editorial

Authors

ACAnastasia ChrysostomouThe Royal Melbourne HospitalGBGavin J. BeckerTufts University

Discussion

Loading...

Member takes

Implication

May support adjunctive spironolactone for proteinuria reduction; hypothesis-generating and requires randomized confirmation.

Structured PICO

Does spironolactone in addition to ACE inhibition reduce proteinuria in patients with chronic renal disease?

P
Population
Patients with chronic renal disease
I
Intervention
Spironolactone in addition to ACE inhibition
O
Outcome
Proteinuria reductionsurrogate

This letter discusses the potential of adding spironolactone to ACE inhibitors to reduce proteinuria in chronic renal disease.

Cite This Study

Chrysostomou et al. (2001) studied this question. Spironolactone added to ACE inhibition reduces proteinuria in patients with chronic renal disease.

synapsesocial.com/papers/6a5a8b8a4bab1debbe562b3chttps://doi.org/10.1056/nejm200109203451215
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Effect of spironolactone combined with angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers on chronic glomerular disease2013 · 12 citations
  2. 2Effects of Spironolactone in Combination with Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers in Patients with Proteinuria2014 · 13 citations
  3. 3Double-Blind, Placebo-Controlled Study on the Effect of the Aldosterone Receptor Antagonist Spironolactone in Patients Who Have Persistent Proteinuria and Are on Long-Term Angiotensin-Converting Enzyme Inhibitor Therapy, with or without an Angiotensin II Receptor Blocker2006 · 211 citations
  4. 4Spironolactone in Combination with Cilazapril Ameliorates Proteinuria and Renal Interstitial Fibrosis in Rats with Anti-Thy-1 Irreversible Nephritis2004 · 28 citations
  5. 5Low-dose spironolactone, added to long-term ACE inhibitor therapy, reduces blood pressure and urinary albumin excretion in obese patients with hypertensive target organ damage2009 · 34 citations